Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of GW406381 versus placebo and celecoxib in adults with rheumatoid arthritis
2005-000158-61Phase 3Completed
- Sponsor
- GSK
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GW406381 in rheumatoid arthritis (RA) (6 arms), sponsored by GSK. Primary endpoint: Percentage of ACR20 responders at Week 12. Started May 2005; status: completed.
02
Drugs
GW406381
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-000158-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000158-61.